JP2009545598A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545598A5
JP2009545598A5 JP2009522869A JP2009522869A JP2009545598A5 JP 2009545598 A5 JP2009545598 A5 JP 2009545598A5 JP 2009522869 A JP2009522869 A JP 2009522869A JP 2009522869 A JP2009522869 A JP 2009522869A JP 2009545598 A5 JP2009545598 A5 JP 2009545598A5
Authority
JP
Japan
Prior art keywords
alkyl
carbon
hydrogen
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009522869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017244 external-priority patent/WO2008016675A1/en
Publication of JP2009545598A publication Critical patent/JP2009545598A/ja
Publication of JP2009545598A5 publication Critical patent/JP2009545598A5/ja
Pending legal-status Critical Current

Links

JP2009522869A 2006-08-01 2007-08-01 Ｐ３８キナーゼ阻害剤 Pending JP2009545598A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82111606P 2006-08-01 2006-08-01
PCT/US2007/017244 WO2008016675A1 (en) 2006-08-01 2007-08-01 P38 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2009545598A JP2009545598A (ja) 2009-12-24
JP2009545598A5 true JP2009545598A5 (https=) 2010-09-16

Family

ID=38705006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009522869A Pending JP2009545598A (ja) 2006-08-01 2007-08-01 Ｐ３８キナーゼ阻害剤

Country Status (4)

Country Link
US (1) US8119798B2 (https=)
EP (1) EP2059512A1 (https=)
JP (1) JP2009545598A (https=)
WO (1) WO2008016675A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010259023A1 (en) * 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
AU2011336764B2 (en) 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
WO2020124213A1 (en) 2018-12-20 2020-06-25 Krylov Sergey N Binder selection using capillary electrophoresis
EP3772513A1 (en) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036410A1 (en) 1998-01-13 1999-07-22 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
US6262053B1 (en) 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
CA2394727A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
CA2451125A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US20030139435A1 (en) 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003032903A2 (en) 2001-10-12 2003-04-24 New York University Trisubstituted triazines compounds with antitubulin activity
FR2841116B1 (fr) 2002-06-19 2004-11-26 Seb Sa Cafetiere du type expresso a reservoir d'eau amovible
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
JP2008540585A (ja) 2005-05-19 2008-11-20 プロメティック・バイオサイエンスィズ・インコーポレーテッド 転移性メラノーマ及び他の癌を治療するための化合物、そのような化合物を含有する組成物、および治療方法
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library

Similar Documents

Publication Publication Date Title
JP2009545598A5 (https=)
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
JP2011529049A5 (https=)
JP2010525056A5 (https=)
WO2012147107A3 (en) Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition
EP2620432A3 (en) Diarylhydantoin compounds
SI3009431T1 (en) 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer
JP2016522835A5 (https=)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
GEP20125469B (en) Inhibitors of akt activity
JP2015517566A5 (https=)
NZ588830A (en) Inhibitors of protein kinases
CA2687265A1 (en) P70 s6 kinase inhibitors
JP2014505107A5 (https=)
JP2017504611A5 (https=)
JP2016526540A5 (https=)
RU2011108026A (ru) Комбинированная терапия туберкулеза
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
JP2011513410A5 (https=)
TN2012000110A1 (en) N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
JP2011521938A5 (https=)
EP3255043A3 (en) N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3- methylazetidine-1-sulfonamide as chemokine receptor modulator
JP2010522218A5 (https=)
EA200870454A1 (ru) Способ ингибирования c-kit киназы
SI3174881T1 (en) (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases